search
Back to results

InterTAN: Integrated Dual Screw Design Improve Biomechanics/Function Following Fixation Surgery

Primary Purpose

Fracture of Hip

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Synthes TFNA
Trigen InterTAN
Sponsored by
Paul E. Matuszewski
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Fracture of Hip focused on measuring Surgical Fixation, Cephalomedullary nail

Eligibility Criteria

55 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Non-pathologic fractures OTA/AO classification 31A2, 31A3 fractures Ability to participate in 4-MET equivalent activities without ambulatory assistance prior to injury Exclusion Criteria: Inability to consent Inability to participate in follow-up activities History of chronic pain / current opioid treatment Pre-injury ambulatory status requiring assistance device Neurological condition altering gait or sensation (e.g. History of stroke with altered gait, peripheral neuropathy).

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Active Comparator

    Arm Label

    Trigen InterTan

    Synthes TFNA

    Arm Description

    Patients in this arm will be implanted with the cephalomedullary nail Trigen InterTan manufactured by Smith & Nephew.

    Patients in this arm will be implanted with the single-screw device TFNA manufactured by DePuy Synthes.

    Outcomes

    Primary Outcome Measures

    Change in self-reported physical function
    Patient Reported Outcomes Measurement Information System (PROMIS) Physical Function Questionnaire is a 53 question survey with a five point Likert scale ranging from 1 to 5 where a higher number indicates less physical function.
    Change in self-reported pain
    Patient Reported Outcomes Measurement Information System (PROMIS) Pain Interference Questionnaire is a 56 question survey with a five point Likert scale ranging from 1 to 5 where a higher number indicates increased interference due to pain.

    Secondary Outcome Measures

    Change in Functional Independence Measure
    The Functional Independence Measure (FIM) is a tool used to measure the level of disability as well as the change in patient status. FI is comprised of 18 items, grouped into 2 subscales - motor and cognition. Each item is scored on a 7 point ordinal scale, ranging from a score of 1 to a score of 7. The higher the score, the more independent the patient is in performing the task associated with that item.
    Change in pain assessment
    Brief Pain Inventory (BPI) will be used to measure pain intensity. This is a four-item scale that measures current, worst, least, and average pain. Each of these four items are measured on a numeric scale from 0 to 10 with 0 being ''no pain'' and 10 being ''severe pain.''
    Change in weight bearing
    The ground reaction forces of the injured and non injured limb will be evaluated over the course of recovery to assess when loading between limbs becomes symmetric during their physical therapy.
    Change in Visual Analog Pain Score
    The visual analog pain score is a horizontal line with a scale ranging from 0 to 10 where a higher number indicates more pain.

    Full Information

    First Posted
    April 13, 2022
    Last Updated
    August 31, 2023
    Sponsor
    Paul E. Matuszewski
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT06024304
    Brief Title
    InterTAN: Integrated Dual Screw Design Improve Biomechanics/Function Following Fixation Surgery
    Official Title
    Does an Integrated Dual Screw Design Improve Biomechanics and Function Following Fixation of Unstable Intertrochanteric Femur Fractures: A Randomized Pilot Trial (InterTAN)
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    August 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    January 1, 2024 (Anticipated)
    Primary Completion Date
    January 1, 2026 (Anticipated)
    Study Completion Date
    January 1, 2027 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor-Investigator
    Name of the Sponsor
    Paul E. Matuszewski

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Product Manufactured in and Exported from the U.S.
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The goal of this pilot, patient blinded randomized trial is to develop a mechanistic understanding of gait following fixation of unstable intertrochanteric hip fractures and return to function and pain control. The guiding hypothesis that will be tested in a subsequent clinicial trial is that the InterTAN when compared to standard lag-screw cephalomedullary nails will have decreased post operative pain, earlier return to symmetric weight bearing, and quicker return to pre-injury functioning levels.
    Detailed Description
    Aim 1: Determine the feasibility of conducting a randomized trial assessing gait mechanics as well as outcomes following unstable intertrochanteric femur fractures treated with cephalomedullary nails. This will be achieved by performing a pilot randomized trial comparing the InterTAN versus a single-screw design cephalomedullary nail (SSCMN). Deliverable: Preliminary data to support a larger randomized trial powered on either mechanical assessments or patient reported outcomes. Feasibility of conducting comprehensive biomechanical and patient related outcome measurements in the geriatric hip fracture population. Aim 2: Determine the pathway to return to function and symmetric weight bearing. Load bearing will be assessed through insole monitoring during their inpatient stay and 2-weeks post-op. Additionally, analysis will be performed to measure gait for hip motion, loading, strength and functional assessments at 6,12, and 26 weeks post-op. Patients will also be assessed at 1-year for reported function as well. Hypothesis: Patients in the InterTAN group will have faster return to symmetrical weight bearing/motion and earlier return to function. Deliverable: Longitudinal data assessing return to function and weight bearing in intertrochanteric femur fractures. Aim 3: Determine if use of the InterTAN device when compared to SSCMN results in decreased pain following unstable intertrochanteric femur fractures. Patients will be enrolled in a prospective trial with standardized pain control regimen, assessing patients for pain during their hospital stay using Area Under the Curve Analysis of Visual Analogue Pain Scores at 24, 48 and 72 hours. Similarly, opioid usage in morphine milligram equivalents will be assessed. Pain will be assessed at follow-up visits 6, 12, 26, 52 weeks. Hypothesis: The InterTAN will result in decreased pain in the immediate post-operative period and in sub-acute post-operative period. Aim 4: Determine if the use of the InterTAN device when compared to SSCMN results in decreased healthcare utilization. Participation with therapy, hospital length of stay, discharge disposition, and time-spent in rehabilitation facility will be assessed. Hypothesis: Patients in the InterTAN group will be more likely to be discharged home, participate with therapy more, have decreased length of stay in both inpatient and outpatient units. Deliverable: Data to inform the power analysis for a larger prospective clinical trial.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Fracture of Hip
    Keywords
    Surgical Fixation, Cephalomedullary nail

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Model Description
    Pilot, patient blinded randomized trial
    Masking
    Participant
    Allocation
    Randomized
    Enrollment
    30 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Trigen InterTan
    Arm Type
    Active Comparator
    Arm Description
    Patients in this arm will be implanted with the cephalomedullary nail Trigen InterTan manufactured by Smith & Nephew.
    Arm Title
    Synthes TFNA
    Arm Type
    Active Comparator
    Arm Description
    Patients in this arm will be implanted with the single-screw device TFNA manufactured by DePuy Synthes.
    Intervention Type
    Device
    Intervention Name(s)
    Synthes TFNA
    Intervention Description
    Surgical fixation with single-screw device Synthes TFNA; Pelvic fractures will be repaired utilizing single-screw device Synthes TFNA.
    Intervention Type
    Device
    Intervention Name(s)
    Trigen InterTAN
    Intervention Description
    Surgical fixation with Smith and Nephew Trigen InterTAN cephalomedullary long nail; Pelvic fractures will be repaired utilizing Smith and Nephew Trigen InterTAN.
    Primary Outcome Measure Information:
    Title
    Change in self-reported physical function
    Description
    Patient Reported Outcomes Measurement Information System (PROMIS) Physical Function Questionnaire is a 53 question survey with a five point Likert scale ranging from 1 to 5 where a higher number indicates less physical function.
    Time Frame
    2 weeks, 6 weeks, 12 weeks, 26 weeks, 12 months
    Title
    Change in self-reported pain
    Description
    Patient Reported Outcomes Measurement Information System (PROMIS) Pain Interference Questionnaire is a 56 question survey with a five point Likert scale ranging from 1 to 5 where a higher number indicates increased interference due to pain.
    Time Frame
    2 weeks, 6 weeks, 12 weeks, 26 weeks, 12 months
    Secondary Outcome Measure Information:
    Title
    Change in Functional Independence Measure
    Description
    The Functional Independence Measure (FIM) is a tool used to measure the level of disability as well as the change in patient status. FI is comprised of 18 items, grouped into 2 subscales - motor and cognition. Each item is scored on a 7 point ordinal scale, ranging from a score of 1 to a score of 7. The higher the score, the more independent the patient is in performing the task associated with that item.
    Time Frame
    2 weeks, 6 weeks, 12 weeks, 26 weeks, 12 months
    Title
    Change in pain assessment
    Description
    Brief Pain Inventory (BPI) will be used to measure pain intensity. This is a four-item scale that measures current, worst, least, and average pain. Each of these four items are measured on a numeric scale from 0 to 10 with 0 being ''no pain'' and 10 being ''severe pain.''
    Time Frame
    2 weeks, 6 weeks, 12 weeks, 26 weeks, 12 months
    Title
    Change in weight bearing
    Description
    The ground reaction forces of the injured and non injured limb will be evaluated over the course of recovery to assess when loading between limbs becomes symmetric during their physical therapy.
    Time Frame
    2 weeks, 6 weeks, 12 weeks, 26 weeks, 12 months
    Title
    Change in Visual Analog Pain Score
    Description
    The visual analog pain score is a horizontal line with a scale ranging from 0 to 10 where a higher number indicates more pain.
    Time Frame
    2 weeks, 6 weeks, 12 weeks, 26 weeks, 12 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    55 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Non-pathologic fractures OTA/AO classification 31A2, 31A3 fractures Ability to participate in 4-MET equivalent activities without ambulatory assistance prior to injury Exclusion Criteria: Inability to consent Inability to participate in follow-up activities History of chronic pain / current opioid treatment Pre-injury ambulatory status requiring assistance device Neurological condition altering gait or sensation (e.g. History of stroke with altered gait, peripheral neuropathy).
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Paul E Matuszewski, MD
    Phone
    (859) 323-5533
    Email
    pmatuszewski@uky.edu
    First Name & Middle Initial & Last Name or Official Title & Degree
    Matthew Eubank
    Phone
    (859) 323-5533
    Email
    mseuba01@uky.edu
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Paul Matuszewski, MD
    Organizational Affiliation
    University of Kentucky
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    InterTAN: Integrated Dual Screw Design Improve Biomechanics/Function Following Fixation Surgery

    We'll reach out to this number within 24 hrs